Feedback
Settings

Settings

Goto Application

75,143 results
Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC_EX:A61K39/395

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 7,515
1.WO/2026/102297ANTIBODY OLIGONUCLEOTIDE CONJUGATES FOR TREATING DISEASE
WO - 15.05.2026
Int.Class A61K 31/7105
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7088Compounds having three or more nucleosides or nucleotides
7105Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
 Appl.No PCT/US2025/054619 Applicant STUART, William Inventor STUART, William
Disclosed herein are antibody-oligonucleotide conjugates, pharmaceutical compositions, and methods for treating Sickle Cell Disease. The disclosure contemplates compositions and methods capable of binding a human hematopoietic stem cell marker conjugated to an oligonucleotide capable of hybridizing a target sequence. In some embodiments, the target sequence is a BCL11A transcript sequence. In some embodiments of the disclosure, the antibody-oligonucleotide conjugate promotes antisense- and/or RNA interference-mediated inhibition of BCL11A.
2.WO/2026/099807TYPE-I INTERFERON RESPONSE AND EXHAUSTION GENE SIGNATURE AS A BIOMARKER FOR CANCER IMMUNOTHERAPY
WO - 15.05.2026
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
 Appl.No PCT/IB2025/061397 Applicant UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION Inventor FERRIS, Robert, Louis
Provided herein is a method of treating a patient having a tumor, including determining whether one or more immune cells from the patient express an exhaustion phenotype and administering to the patient one or more therapeutic compositions, wherein: the therapeutic composition includes either one or more checkpoint inhibitors (ICIs) in an amount effective to treat the tumor when the one or more immune cells express the exhaustion phenotype or one or more compounds effective to prime the one or more immune cells to respond to one or more ICIs when the one or more cells do not express the exhaustion phenotype.
3.WO/2026/100257TREATMENT OF MALIGNANT TUMOR
WO - 15.05.2026
Int.Class A61K 31/675
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
31Medicinal preparations containing organic active ingredients
66Phosphorus compounds
675having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
 Appl.No PCT/JP2025/034689 Applicant SYMBIO PHARMACEUTICALS LIMITED Inventor KAMITANI, Tetsu
Provided is a method for treating malignant tumor. Provided is a method for treating malignant tumor, the method comprising administering BCV, a pharmaceutically acceptable salt thereof, or a solvate of BCV or the pharmaceutically acceptable salt, and an immunotherapeutic agent to a subject. Alternatively, provided is a pharmaceutical composition for use in the treatment of malignant tumor, wherein the treatment comprises combination treatment to a subject with BCV, a pharmaceutically acceptable salt thereof, or a solvate of BCV or the pharmaceutically acceptable salt, and an immunotherapeutic agent, and wherein the pharmaceutical composition comprises BCV, a pharmaceutically acceptable salt thereof, or a solvate of BCV or the pharmaceutically acceptable salt, or an immunotherapeutic agent.
4.WO/2026/097917BISPECIFIC ANTIBODY AGAINST TL1A AND IL-23 AND USE THEREOF
WO - 15.05.2026
Int.Class C07K 16/46
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
46Hybrid immunoglobulins
 Appl.No PCT/CN2025/108267 Applicant BEIJING VDJBIO CO., LTD Inventor LI, Dongxia
Provided is a bispecific antibody, comprising: a first domain that specifically binds TNF-like ligand 1a (TL1A), and a second domain that specifically binds interleukin-23 (IL-23). Also provided is a method of using the bispecific antibodies for the treatment or prevention of diseases associated with TL1A and/or IL-23.
5.WO/2026/098007NANOBODY TARGETING IL-23A AND USE THEREOF
WO - 15.05.2026
Int.Class C07K 16/24
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
24against cytokines, lymphokines or interferons
 Appl.No PCT/CN2025/116820 Applicant ZHANG, Fan Inventor ZHANG, Fan
The present invention belongs to the technical field of biomedicine. Provided are a nanobody targeting IL-23A and the use thereof. The nanobody comprises a framework region and a complementarity determining region, wherein the framework region comprises FR-H1, FR-H2, FR-H3 and FR-H4 having amino acid sequences as shown in SEQ ID NOs. 4-7, respectively; and the complementary determining region comprises CDR-H1, CDR-H2 and CDR-H3 having amino acid sequences as shown in SEQ ID NOs. 1-3, respectively. The nanobody can be used in the preparation of an antibody drug targeting IL-23A, which is capable of treating related diseases by means of binding to IL-23A.
6.WO/2026/098547ANTIBODY TARGETING CGRP AND USE THEREOF
WO - 15.05.2026
Int.Class C07K 16/26
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
26against hormones
 Appl.No PCT/CN2025/132978 Applicant HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE INC. Inventor QIN, Lingyun
An antibody targeting CGRP and the use thereof. The antibody or antigen-binding portion thereof comprises a heavy chain variable region and a light chain variable region. The heavy chain variable region comprises CDR-H1, CDR-H2 and CDR-H3. The light chain variable region comprises CDR-L1, CDR-L2 and CDR-L3. The antibody can specifically bind to human and rat CGRP polypeptides and α/β subtype CGRP polypeptides with high affinity, block the binding of CGRP to a receptor CGRPR thereof, reduce pain perception, and achieve the treatment of painful diseases such as migraines caused by CGRP. Additionally, the antibody can alleviate or treat hot flushes.
7.WO/2026/098577ANTI-CCR8 ANTIBODY OR ANTIGEN BINDING FRAGMENT THEREOF, AND USE THEREOF
WO - 15.05.2026
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
 Appl.No PCT/CN2025/133127 Applicant GUANGDONG FAPON BIOPHARMA INC. Inventor GUO, Jian
The present application relates to the technical field of biology, and discloses an anti-CCR8 antibody or an antigen binding fragment thereof, and a use thereof. The antibody can specifically bind to at least one epitope of CCR8, can also bind to Treg cells, has ADCC activity, and provides new possibilities for the treatment and/or prevention of cancer.
8.WO/2026/102461α4β7 INTEGRIN ANTIBODY COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE
WO - 15.05.2026
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
 Appl.No PCT/US2025/055009 Applicant SPYRE THERAPEUTICS, INC. Inventor HEW, Kinjal Maniar
Provided herein are variant α4β7 integrin antibodies and methods of use.
9.WO/2026/098441COMPOSITION AND METHOD FOR CANCER TREATMENT USING POLYPEPTIDE CONJUGATES
WO - 15.05.2026
Int.Class C07K 19/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
19Hybrid peptides
 Appl.No PCT/CN2025/132390 Applicant SUZHOU SMARTNUCLIDE BIOPHARMACEUTICAL CO., LTD. Inventor XU, Tao
Provided herein are recombinant polypeptides comprising: (a) an antibody; and (b) a multimerization domain, wherein the antibody is operably linked to the multimerization domain. Provided also relates to methods of administering the recombinant polypeptides during pre-targeted radioimmunotherapy totreat cancer in a subject in need thereof.
10.WO/2026/098621ENGINEERED ANTIBODY WITH SITE-SPECIFIC CONJUGATION, ANTIBODY-DRUG CONJUGATE, AND APPLICATION THEREOF
WO - 15.05.2026
Int.Class C07K 16/18
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
 Appl.No PCT/CN2025/133367 Applicant BLISS BIOPHARMACEUTICAL (HANGZHOU) CO., LTD. Inventor XIA, Bing
Disclosed are an engineered antibody with site-specific conjugation, an antibody-drug conjugate, and an application thereof. The engineered antibody with site-specific conjugation is an IgG antibody, wherein a cysteine at a position corresponding to an interchain disulfide bond-forming site in a wild-type IgG antibody is substituted and/or deleted; and the IgG antibody does not have a disulfide bond or a free sulfhydryl group between heavy and light chains. The antibody of the present invention can be site-specifically conjugated to DAR4 ADC, and the resulting ADC has a uniform DAR value, high homogeneity, low batch-to-batch variability, and is suitable for large-scale production.
# -